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Abstract
Background. Dopaminergic imaging has high diagnostic accuracy for dementia with Lewy
bodies (DLB) at the dementia stage. We report the first investigation of dopaminergic imaging
at the prodromal stage.
Methods. We recruited 75 patients over 60 with mild cognitive impairment (MCI), 33 with
probable MCI with Lewy body disease (MCI-LB), 15 with possible MCI-LB and 27 with MCI
with Alzheimer’s disease. All underwent detailed clinical, neurological and neuropsychological
assessments and FP-CIT [123I-N-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)] dopa-
minergic imaging. FP-CIT scans were blindly rated by a consensus panel and classified as nor-
mal or abnormal.
Results. The sensitivity of visually rated FP-CIT imaging to detect combined possible or prob-
able MCI-LB was 54.2% [95% confidence interval (CI) 39.2–68.6], with a specificity of 89.0%
(95% CI 70.8–97.6) and a likelihood ratio for MCI-LB of 4.9, indicating that FP-CIT may be a
clinically important test in MCI where any characteristic symptoms of Lewy body (LB) disease
are present. The sensitivity in probable MCI-LB was 61.0% (95% CI 42.5–77.4) and in possible
MCI-LB was 40.0% (95% CI 16.4–67.7).
Conclusions. Dopaminergic imaging had high specificity at the pre-dementia stage and gave a
clinically important increase in diagnostic confidence and so should be considered in all
patients with MCI who have any of the diagnostic symptoms of DLB. As expected, the sen-
sitivity was lower in MCI-LB than in established DLB, although over 50% still had an abnor-
mal scan. Accurate diagnosis of LB disease is important to enable early optimal treatment for
LB symptoms.
Background
Prodromal dementia may include different patterns of symptom onset and presentation
(McKeith et al. 2016), but here we use it synonymously with mild cognitive impairment
(MCI), i.e. for the cognitive presentation. Biomarkers are likely to be important for improving
diagnostic accuracy in MCI and are included in the published criteria for MCI due to
Alzheimer’s disease (AD) (Albert et al. 2011; Dubois et al. 2014). In dementia with Lewy bod-
ies (DLB), clinical studies report the diagnostic value of dopaminergic imaging, especially FP-
CIT [123I-N-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)] nortropane single-photon
emission computed tomography (O’Brien et al. 2014), and we reported similar accuracy of
FP-CIT validated against autopsy (Thomas et al. 2017).
Only a few studies, all retrospective (e.g. Auning et al. 2011; Chiba et al. 2012), have assessed
the clinical features of MCI stage of Lewy body (LB) disease [summarised in a review by (Donaghy
et al. 2015)]. In our previous report on this cohort, we found that using supportive neuropsychi-
atric symptoms, as defined in the 2017 DLB diagnostic criteria (McKeith et al. 2017), usefully dis-
tinguished MCI with Lewy body disease (MCI-LB) from MCI with AD (MCI-AD) (Donaghy
et al. 2018). In contrast, although MCI-LB subjects scored lower on tests of attention, visuospatial
function and verbal fluency, these did not accurately differentiate MCI-LB from MCI-AD
(Donaghy et al. 2018). Others have examined the neurocognitive profile and reported that amnes-
tic MCI predicts conversion to AD whilst non-amnestic MCI is associated with DLB (Ferman
et al. 2013). However, there have been no reports of the utility of dopaminergic imaging in MCI.
We therefore investigated the diagnostic value of FP-CIT dopaminergic imaging in a pro-
spective study of a cohort of MCI followed up for over a year. We hypothesised that FP-CIT
would have similar specificity but lower sensitivity at the MCI stage where the impact on
nigrostriatal neurones will be less than at dementia stage, and that this would result in an over-
all improvement in diagnostic confidence of MCI-LB as estimated using likelihood ratios.
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Methods
Individual symptoms and final diagnosis by consensus panel
Details of recruitment, clinical assessment and clinical diagnoses
have been reported previously (King et al. 2017; Donaghy et al.
2018). Briefly, study subjects were over 60 years of age and
recruited from memory clinics, specialist dementia services, eld-
erly medicine clinics and neurology clinics in the North East of
England. They had been diagnosed with MCI in these services
and were eligible for the study if at some stage they were reported
to have at least one clinical symptom suggesting the possible pres-
ence of DLB, e.g. autonomic symptoms, visual disturbances, olfac-
tory impairment and mood changes, as well as any indication of
the presence of core and suggestive features of DLB.
All subjects provided written informed consent in accordance
with our ethical approval, following which they had a detailed
standardised neuropsychological assessment by a research nurse
or psychologist and a thorough diagnostic medical assessment
by a board certified old age psychiatrist (PD), including blood
sampling, lumbar puncture and neurological examination. After
this, subjects underwent FP-CIT imaging (see below for details).
This report focuses on FP-CIT findings in this MCI population.
We have previously reported the clinical symptoms and neuro-
psychological findings in our earlier paper (Donaghy et al.
2018). So we report only key summary descriptive neuropsycho-
logical and clinical data here. Study subjects were reviewed after
a year and the detailed clinical assessment was repeated.
An expert consensus clinical panel (AT, PD, J-PT) reviewed all
the clinical assessment data to confirm that subjects met National
Institute on Aging-Alzheimer’s Association (NIA-AA) criteria for
MCI without considering aetiology (Albert et al. 2011). The consen-
sus panel also rated the presence or absence of each of the four core
clinical LB symptoms characteristic of DLB in the fourth consensus
report of the DLB consortium [cognitive fluctuations, complex
visual hallucinations, clinical parkinsonism, clinical probable rapid
eye movement (REM) sleep behaviour disorder (RBD)] (McKeith
et al. 2017). This consensus panel approach has been validated
previously against autopsy diagnoses (McKeith et al. 2000, 2007).
As described previously (King et al. 2017; Donaghy et al.
2018), subjects were allocated in one of the three clinical diagno-
ses: probable MCI-LB (NIA-AA MCI plus two or more of the
four clinical core LB symptoms), possible MCI-LB (MCI plus
one of the four symptoms) and MCI-AD (MCI with none of
these four symptoms and evidence of decline which was a char-
acteristic of AD with no evidence for another aetiology, i.e. they
met the additional NIA-AA criterion of ‘aetiology of MCI consist-
ent with AD pathophysiologic process’). The ‘1-year rule’ was
applied so that no subjects had had evidence of Parkinsonism
for more than a year before the onset of their cognitive decline.
Assignment to these diagnostic categories was based on the infor-
mation from both baseline and annual follow-up clinical evalua-
tions. The consensus panel assessment of both MCI and LB
symptoms, and allocation to diagnostic category at both time
points, was done blind to FP-CIT results.
Acquisition of FP-CIT images
Three to six hours following a bolus intravenous injection of
185 MBq of 123I-FP-CIT (DaTSCAN, GE Healthcare, UK),
patients were scanned (25 min) using a double-headed γ camera
(Siemens Symbia S) fitted with a low-energy high-resolution par-
allel hole collimator. One hundred and twenty (60 per detector)
25 s views over a 360° orbit were acquired on a 128 × 128 matrix
with a zoom of 1.23× giving a pixel size of 3.9 mm × 3.9 mm.
Image processing and display were then performed on a
Hermes workstation (Hermes Medical Solutions, Stockholm,
Sweden). Images were reconstructed without attenuation correc-
tion using filtered back projection and a Butterworth filter
(order 10, cut-off 1.3 cycles/cm). Transverse sections were then
manually reoriented to correct for any head tilt and to provide
a consistent display.
Visual rating of FP-CIT images
Visual assessment of all scans was undertaken blind to clinical
diagnosis and information by four raters: one consultant medical
physicist experienced in nuclear medicine reporting, one experi-
enced neuroimaging analyst and certified old age psychiatrists
(JL, SJC, AT, PD). Prior training for this task involved all raters
reading details of the visual rating scale in advance and having
previous experience in the use of the scale (Benamer et al.
2000), as well as visual inspection of an independent dataset of
10 scans ranging from normal to markedly abnormal to allow
raters to see the full range of scan appearances. Our group has
extensive experience in FP-CIT rating and, e.g. had inter-rater
reliability (intra-class correlation coefficient 0.93) when reporting
FP-CIT in a recent study in people with dementia (Lloyd et al.
2018). Then, for the rating session, all scans were independently
randomised and blinded from clinical data before being presented
to each rater. Using an identical colour map scaled to the
maximum voxel count, transverse sections were displayed with
the cross-platform image viewer ‘MRIcron’ (https://www.nitrc.
org/projects/mricron). Scans were rated independently by each
panel member using an established four-category FP-CIT visual
rating procedure (Benamer et al. 2000), which has also showed
diagnostic value in the differential diagnosis of DLB and AD
(O’Brien et al. 2004). Briefly: grade 0 (bilateral tracer uptake in
caudate and putamen and largely symmetric); grade 1 (asymmet-
ric uptake with normal or almost normal putamen activity in one
hemisphere with more marked reduction in the contralateral
putamen); grade 2 (significant bilateral reduction in putamen
uptake with activity confined to the caudate) and grade 3 (signifi-
cant bilateral reduction in uptake affecting both the caudate and
the putamen). After rating all scans, any scan where there was
no complete agreement between all raters was then subsequently
reviewed by all four raters together where a consensus rating
was agreed. All scans were rated as normal or abnormal and
where abnormal were graded as 1–3. In addition to primary visual
reading, all scans underwent semi-quantitative analysis using
DaTQUANT software (v1.0, GE Healthcare), comparing study
scans against age-adjusted norms, to ensure no FP-CIT scans
with significant balanced striatal loss (i.e. abnormal scans) were
inadvertently rated as normal. Following this semi-quantitative
analysis, no scans were reclassified as abnormal.
Statistical analysis
The Statistical Package for Social Sciences software (SPSS version
23) was used for statistical evaluation. For group comparisons, χ2
tests were used for categorical variables, and for continuous vari-
ables, we tested for normality of distribution and t tests or Mann–
Whitney tests were used. Diagnostic accuracy of FP-CIT (sensitiv-
ity, specificity and overall accuracy) was calculated from standard
2 × 2 frequency tables, and 95% confidence was calculated using
2 Alan J. Thomas et al.
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Minitab (version 16.1). Likelihood ratios were then calculated to
estimate the potential-added diagnostic value of using FP-CIT
imaging.
Results
A total of 90 subjects consented to the study. However, 15 did not
meet entry criteria after full baseline assessment or withdrew
before or declined the FP-CIT scan. Thus, 75 subjects met all cri-
teria and completed baseline assessments and FP-CIT imaging
(see Fig. 1).
After assessment by the diagnostic panel, 33 subjects were
found to have two or more core LB symptoms and were classified
as probable MCI-LB. Fifteen had one symptom and were classed
as possible MCI-LB. Twenty-seven were found not to have any
diagnostic LB symptoms and were classed as MCI-AD. In these
cases, any symptoms indicating core features of LB disease,
which had been identified by the referring service, were not con-
firmed by the detailed research assessment, e.g. a reported tremor
was not parkinsonian and there were no other features of
Parkinson’s disease (PD); or the symptoms indicating possible
LB disease, e.g. constipation or anosmia, were present but no
core or suggestive diagnostic features of LB disease were present.
No subject had evidence of neuroleptic sensitivity.
Table 1 shows the demographic and clinical characteristics of
the three groups. There were no differences across the groups in
age, gender or severity of cognitive impairment, with the mean
Mini-Mental State Examination (MMSE) score being over 26
and mean Clinical Dementia Rating (CDR) score being <0.5, con-
sistent with the MCI status of study subjects. The overall physical
health status of the subjects was similar on the Cumulative Illness
Rating Scale for Geriatrics (CIRS-G), with the great majority of
subjects scoring 0–2 on this scale (meaning they had only mild
disability or moderate disability controlled by first-line therapy),
and similar to previous reports at the MCI stage (e.g. Borson
et al. 2010).
As expected, the MCI-LB groups had higher scores on
the Hoehn and Yahr scale and Movement Disorder Society
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and
had more impairment on the Instrumental Activities of Daily
Living (IADL) scale due to their combined physical and mental
impairments. Consistent with the diagnosis, the MCI-LB
groups had higher sleepiness (Epworth Sleepiness Scale), depres-
sion (Geriatric Depression Scale) and behavioural disturbance
(Neuropsychiatric Inventory).
FP-CIT visual rating
Table 2 shows that abnormal FP-CIT findings were found in 61%
of probable MCI-LB and 40% of possible MCI-LB. Three MCI-
AD subjects were rated as having an abnormal FP-CIT scan (all
were classified as grade 1). Abnormal scans were more frequent
in the MCI-LB groups than in the MCI-AD group whether
assessed as normal v. abnormal or by grade on the visual rating
scale. But the probable and possible MCI-LB were not different
from each other in the frequency of abnormal FP-CIT. Of the
26 subjects with abnormal FP-CIT scans in the MCI-LB groups,
only 12 (46%) had clinical parkinsonism on neurological examin-
ation, and thus only 41% of people overall with abnormal scans
had parkinsonism (12 of 29 abnormal scans). The mean κ for
inter-rater reliability was 0.59, and for intra-rater reliability it
was 0.73.
Overall the sensitivity of visually rated FP-CIT imaging to
detect combined possible and or probable MCI-LB was 54.2%
[95% confidence interval (CI) 39.2–68.6], with a specificity of
89.0% (95% CI 70.8–97.6), giving an overall diagnostic accuracy
of 66.6% (95% CI 54.8–77.0). The sensitivity in probable MCI-
LB was 61.0% (95% CI 42.5–77.4), and in possible MCI-DLB it
was 40.0% (95% CI 16.4–67.7).
The likelihood ratio for MCI-LB was therefore 4.9, indicating
that FP-CIT dopaminergic imaging may be a clinically important
test.
After unblinding, we reviewed the FP-CIT images and
DaTQUANT semi-quantification data on the three abnormal
scans in patients diagnosed with MCI-AD and confirmed that
these were indeed abnormal scans. We were also able to review
the progression of these subjects over the 1-year follow-up, and
only one developed any core or suggestive features of LB disease
by the 1-year review. This subject developed cognitive fluctua-
tions. Two of these subjects consented to having cardiac metaio-
dobenzylguanidine (MIBG) scans in another study (the third,
who had developed cognitive fluctuations, declined) and both of
these scans were abnormal.
By the time all surviving subjects had had at least 1 year of
clinical review of diagnosis, the mean duration of follow-up was
1.5 years, with 27 subjects having had a second year review and
nine a third year review. Twenty-one subjects had progressed to
dementia, all to the expected disease dementia subtype [14 with
probable DLB (McKeith et al. 2017), three with possible DLB
(McKeith et al. 2017) and four with probable AD dementia
Fig. 1. Classification of subjects. Subjects with two or more diagnostic features were
classified as MCI-LB. Subjects with no diagnostic features were classified as MCI-AD.
Subjects with one diagnostic feature were classified as possible MCI-LB. Prob./Poss
MCI-LB, probable/possible MCI with Lewy bodies; MCIAD, MCI due to Alzheimer’s
disease.
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(McKhann et al. 2011)], and five had died. Of those who had
died, four had consented to brain tissue donation. Detailed neuro-
pathological examination of these four subjects found neuropath-
ology consistent with their clinical diagnoses. Two had been
diagnosed as MCI-LB and both had neocortical LB disease and
met the McKeith criteria for DLB. The other two had MCI-AD
and both met the NIA-AA criteria for neuropathological change
due to AD.
Table 1. Demographic and clinical data for the three MCI groups
Probable
MCI-LBa N = 33
Possible
MCI-LBa N = 15 MCI-ADa N = 27
aProbable MCI-LB = A;
possible MCI-LB = B; MCI-AD = C
Age (years) 75.0 (7.5) 75.9 (8.3) 77.2 (7.8) F(2,72) = 0.60, p = 0.55
Gender (M:F) 22:11 9:6 11:16 X = 4.17, df = 2,
p = 0.12
MMSE 26.5 (1.8) 25.9 (2.9) 26.5 (2.2) F(2,72) = 0.41, p = 0.67
ACE-R 79.3 (7.7) 78.0 (13.4) 79.7 (11.2) F(2,72) = 0.14, p = 0.87
CDR 0.45 (0.15) 0.43 (0.18) 0.44 (0.16) F(2,72) = 0.1, p = 0.91
CIRS-G 8.9 (4.2) 12.2 (5.1) 8.8 (3.8) F(2,72) = 3.7, p = 0.03
A v. B = 0.02,
A v. C = 0.93,
B v. C = 0.02
IADL 14.6 (5.1) 12.3 (3.4) 9.9 (2.1) F(2,55) = 7.7, p = 0.001,
A v. B = 0.12,
A v. C = p < 0.001,
B v. C = p = 0.05
UPDRS 26.7 (15.8) 15.5 (11.8) 14.6 (6.9) F(2,72) = 8.3, p = 0.001,
A v. B, p = 0.01,
A v. C, p < 0.001,
B v. C, p = 0.74
H&Y (stages: 0/1/2/3/4/5) 18/0/7/7/1/0 13/0/1/1/0/0 27/0/0/0/0/0 X = 18.5, df = 6,
p = 0.005,
A v. B = p = 0.19,
A v. C = p = 0.001,
B v. C = p = 0.15
ESS 10.8 (5.4) 7.8 (3.7) 4.4 (3.9) F(2,72) = 14.3, p < 0.001,
A v. B = p = 0.03,
A v. C = p < 0.001,
B v. C = p = 0.01
NPI 13.4 (9.5) 14.3 (12.6) 6.1 (6.8) F(2,64) = 4.8, p = 0.012,
A v. B = p = 0.80,
A v. C = p = 0.003,
B v. C = p = 0.04
NPI distress 7.8 (7.2) 7.9 (6.9) 3.0 (4.5) F(2,64) = 5.0, p = 0.009
A v. B = 0.64,
A v. C = 0.008,
B v. C = 0.003
GDS 4.4 (3.5) 3.6 (3.3) 2.2 (2.2) F(2,72) = 4.2, p = 0.019
A v. B = 0.45,
A v. C = 0.005,
B v. C = 0.09
Medication at baseline number (percentage)
Anti-dementia 17 (51.5) 0 (0) 7 (25.9) X = 13.3, df = 2,
p = 0.001
Anti-parkinsonian 7 (21.2) 1 (6.6) 0 (0) X = 7.3, df = 2,
p = 0.03
Antipsychotic 2 (6.1) 0 (0) 0 (0) X = 2.61, df = 2,
p = 0.27
Antidepressant 11 (33.3) 7 (46.7) 11 (40.7) X = 0.85, df = 2,
p = 0.65
MMSE, Mini-mental State Examination; ACE-R, Addenbrooke’s Cognitive Examination – Revised; CDR, Clinical Dementia Rating scale; CIRS-G, Cumulative Illness Rating Scale for Geriatrics;
IADL, Instrumental Activities of Daily Living scale; UPDRS, Unified Parkinson’s Disease Rating Scale – Part III; H&Y, Hoehn and Yahr rating scale; ESS, Epworth Sleepiness Scale; NPI,
Neuropsychiatric Inventory; GDS, Geriatric Depression Scale.
aProbable MCI-LB = A; possible MCI-LB = B; MCI-AD = C.
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Discussion
We report here for the first time, the performance of dopamin-
ergic imaging at the MCI stage of cognitive decline. Compared
with MCI-AD, dopaminergic imaging had an 89% specificity
for MCI-LB and a positive likelihood ratio of 4.9, i.e. a positive
(abnormal) scan increases the absolute probability of having
MCI-LB by about 30% (McGee, 2002), which is a clinically
important increase. This suggests that the use of FP-CIT imaging
at the MCI stage in people with any symptom characteristic of LB
disease may be clinically useful. As hypothesised, because of less
advanced nigrostriatal degeneration in earlier disease, we also
found that at this stage of illness the sensitivity was lower
(54.2%) compared with 80% at the dementia stage (O’Brien
et al. 2014).
It is important to note that a large proportion (40%) of
patients with only a single-core diagnostic symptom of DLB (cog-
nitive fluctuations, motor parkinsonism, complex visual halluci-
nations and REM sleep behaviour disorder) had abnormal
FP-CIT at this early stage, with the proportion with abnormal
scans rising as expected when more such symptoms were present.
It is also important that at this MCI stage, most subjects with
abnormal scans did not have clinical evidence of parkinsonism
(only 41%), demonstrating that biomarkers such as FP-CIT are
able to detect disease in advance of clinical detection of parkin-
sonism and have an important role to play in early diagnosis of
dementia. This figure of 41% compares with 83% of people
with abnormal scans having clinical parkinsonism at the demen-
tia stage (O’Brien et al. 2004), consistent with the earlier stage of
assessment in this study.
These findings therefore support the use of FP-CIT imaging in
people with MCI who have any of these core features of DLB in
order to improve the detection of LB disease and distinguish it
from AD. The value of a diagnostic test depends on its setting.
For the identification of potential disease in the community set-
tings, a high sensitivity is important for screening procedures.
But in specialist settings, it is the specificity that is more import-
ant and a specificity of >80% has been suggested (Postuma et al.
2015). The 89% specificity here supports the value of FP-CIT
imaging in distinguishing MCI-LB from MCI-AD.
Previous work has reported that FP-CIT imaging improves
diagnostic accuracy compared with clinical diagnosis alone
(Walker et al. 2007) and, whilst most studies in dementia have
compared the more certain diagnosis of probable DLB with
AD, two reports have indicated the value of FP-CIT in the less
certain diagnosis of possible DLB, with diagnosis validated by
clinical follow-up as in this study (O’Brien et al. 2009; Walker
et al. 2014). Our findings suggest that FP-CIT has a utility at
the MCI stage as well, and the future progression and diagnoses
of our possible LB-MCI group are of particular interest. Early
and accurate diagnosis of LB disease is important for the same
reasons as early diagnosis of AD and also because it can prevent
the fluctuations that are intrinsic to the disease being mistaken for
delirium, strongly cautious against using antipsychotics and facil-
itates early identification and treatment of motor symptoms, dys-
autonomia and other characteristic non-psychiatric symptoms
(NICE, 2006).
It is possible that the sensitivity, specificity, diagnostic accuracy
and likelihood ratios may be even better. Of the three MCI-AD
subjects with abnormal scans, one has now developed cognitive
fluctuations and the other two have since had abnormal cardiac
MIBG suggesting that their scans may not be false positives. It
may be that both of these biomarkers are picking up, in these
patients, LB disease before any LB clinical symptoms are mani-
fested. The high specificity of FP-CIT in this study is similar to
that reported at the dementia stage, but it is important to remem-
ber that FP-CIT imaging is not a specific marker of synuclein
pathology and that other diseases, e.g. frontotemporal lobar
degeneration, can cause abnormal scans (Tiraboschi et al. 2016;
Thomas et al. 2017). Thus, we cannot exclude the fact that
some of our patients may have early frontotemporal dementia
or other rarer neurodegenerative diseases. Furthermore, it is our
standard practice not to recruit people with evidence on structural
imaging of infarcts in the basal ganglia as these may also cause
false-positive FP-CIT scans, and we recommend that the clini-
cians should conduct structural scans before FP-CIT imaging
where such cerebrovascular disease is suspected.
In addition, at this early stage, it is arguably inappropriate to
say that the sensitivity of FP-CIT is low because many people
with LB disease elsewhere, e.g. in neocortical and limbic areas,
are likely to have insufficient LB disease involvement in the sub-
stantia nigra to produce an abnormal scan. Even at the dementia
stage, we found 10% of people with confirmed LB disease had no
significant nigral involvement (Thomas et al. 2017). Thus, whilst
an abnormal FP-CIT scan strongly supports the presence of LB
disease even at this early stage of illness, a normal scan is probably
Table 2. FP-CIT ratings for probable MCI-LB, possible MCI-LB and MCI-AD
Probable
MCI-LBa N = 33
Possible
MCI-LBa N = 15 MCI-ADa N = 27
Probable MCI-LB = A; possible
MCI-LB = B; MCI-AD = C
Consensus panel rating of FP-CIT number
abnormal (percentage)
20 (61.0) 6 (40.0) 3 (11.1) X = 15.4, df = 2, p < 0.001
A v. B
X = 1.76, df = 1, p = 0.18
A v. C
X = 15.4, df = 1, p < 0.001
B v. C
X = 4.78, df = 1, p = 0.03
Consensus panel semi-quantitative grades
of FP-CIT rating: 0/1/2/3 (percentage)
13/7/9/4 (39/21/27/12) 9/5/1/0 (60/33/7/0) 24/3/0/0 (89/11/0/0) X = 22.4, df = 6, p = 0.001
A v. B
X = 5.48, df = 3, p = 0.14
A v. C
X = 17.4, df = 3, p = 0.001
B v. C
X = 5.32, df = 3, p = 0.07
aProbable MCI-LB = A; possible MCI-LB = B; MCI-AD = C
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more likely to be a false negative than at the dementia stage and
therefore does not rule out LB disease.
This study benefited from being a prospective analysis, from all
subjects having a detailed clinical assessment by an experienced
physician using validated rating scales, from consensus panel
diagnosis and consensus panel rating of all diagnostic symptoms
for DLB and by the FP-CIT ratings being conducted by an experi-
enced panel of raters and confirmed by semi-quantification soft-
ware, which has been demonstrated to improve the accuracy of
ratings (Nicastro et al. 2017). The intra-rater and inter-rater κ
values were lower than in some reported studies (e.g. Seibyl
et al. 2014). This reflects the greater difficulty in rating subjects
whose scans are at an earlier disease stage and where more, there-
fore, have borderline abnormal scans. Furthermore, unlike other
FP-CIT studies, we had no subjects who are generally easier to
rate, such as those with confirmed PD and healthy controls.
The experienced FP-CIT raters when rating the study scans
were aware of how much more difficult such scans were compared
with those in people with more advanced diseases (clinical PD
and DLB) and healthy controls. For example, we had inter-rater
reliability (intra-class correlation coefficient 0.93) when reporting
FP-CIT in a recent study in people with dementia (Lloyd et al.
2018). A key limitation of this study is that the subjects were
largely identified from specialist memory and dementia services
and so are not representative of people either in primary care
or in other specialised secondary care settings, e.g. movement dis-
order clinics. In such settings, the specificity of FP-CIT is lower
(Tiraboschi et al. 2016). All study subjects also had some feature
or features at recruitment initially suggestive of LB disease and so
MCI-AD patients, whilst fulfilling NIA-AA criteria after robust
assessment, may not be representative of the wider MCI-AD
population. However, it is likely that in such a sample of MCI-
AD, the specificity of FP-CIT will be even higher due to a
lower risk of contamination with ‘silent’ LB disease cases, and
thus the performance of FP-CIT will be correspondingly greater.
The conversion rate to dementia has been at the expected rate
of 10–15% per annum for the AD and possible MCI-LB groups
but much higher (about 40%) in the probable MCI-LB in this
cohort. This supports the study population as consisting of people
with neurodegenerative disease, and suggests that the more rapid
decline of people with DLB compared with AD (Mueller et al.
2017) applies also to this earlier MCI stage. The fact that people
converted to the expected dementia subtype provides some valid-
ation of the accuracy of the MCI subtype diagnoses, and is in har-
mony with our use of diagnostic criteria consistent with those for
DLB in the recent fourth report of the DLB consortium.
Furthermore, all four cases who have come to autopsy had neuro-
pathology diagnoses that agreed with their MCI disease diagnosis,
providing some further reassurance about the diagnostic accuracy
in this study. But until more diagnoses are validated against aut-
opsy, they are necessarily less certain than those made at the
dementia stage where the diagnostic criteria have had such tissue
validation.
The fourth revision of the international consensus DLB
criteria (McKeith et al. 2017) were used as the basis for the
MCI-LB diagnoses in this report. This paper deals with the
revised criteria for the dementia stage of cognitive decline asso-
ciated with LB disease. We were able to apply these new consen-
sus DLB criteria core features to our MCI subjects and so the
MCI-LB criteria we used are consistent with these revised DLB
criteria because they elevate clinical RBD (study subjects did
not have polysomnography (PSG) to confirm RBD) to sit
alongside the previous three core diagnostic features as symptoms
for MCI-LB diagnosis. The report also acknowledges the need for
studies such as this which will provide data for evidence-based cri-
teria for improving the diagnosis of LB disease at the MCI stage of
the illness in the future.
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